Skip to content
Accessibility help

Search NICE…

Skip to content

Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE

Search results

Skip to results

Area of interest

Area of interestAntimicrobial prescribing (40)COVID-19 (34)

Type

TypeGuidance (4950)Indicators (319)News (351)NICE advice (498)Quality standards (257)Research recommendations (1786)

Status

StatusAwaiting development (336)Discontinued (461)In consultation (11)In development (430)Published (2572)Topic prioritisation (384)

Last updated

Last updatedLast 3 months (200)Last 6 months (374)Last year (700)Last 3 years (1436)

Guidance programme

Guidance programmeAntimicrobial prescribing guidelines (27)Antimicrobial resistance guidance (2)Cancer service guidelines (10)Clinical guidelines (392)COVID-19 rapid guidelines (27)Diagnostics guidance (89)Health technology evaluations (60)HealthTech guidance (778)Highly specialised technologies guidance (48)Interventional procedures guidance (1001)Medical technologies guidance (147)Medicines practice guidelines (5)NICE guidelines (579)Public health guidelines (89)Safe staffing guidelines (7)Social care guidelines (47)Technology appraisal guidance (2303)

Advice programme

Advice programmeCOVID-19 rapid summaries (8)Evidence summaries (172)Medtech innovation briefings (324)NICE reviews (2)

Showing 2191 to 2205 of 8904 results

Sort by

IgPro20 for treating dermatomyositis [TSID12014]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin [TSID11940]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Olorofim for treating invasive fungal infections in people 16 years and over [TSID11983]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Secukinumab biosimilar for treating plaque psoriasis [TSID11992]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears [TSID8472]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Subcutaneous isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [TSID11969]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Golimumab for treating moderately to severely active ulcerative colitis in people aged 2 to 17 years [TSID11959]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Apremilast for treating moderate to severe plaque psoriasis in people aged 6 to 17 [TSID11921]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Bismuth subcitrate potassium–metronidazole–tetracycline hydrochloride with omeprazole for treating Helicobacter pylori and preventing peptic ulcer relapse [TSID11900]
Topic prioritisation
Result type
Health technology evaluations
Status
Topic prioritisation
TAK-880 for managing primary immunodeficiency diseases in people hypersensitive to IgA [TSID11883]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease in people 12 to 17 years [TSID11887]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Dapsone for treating COVID-19 in people 40 years and over with high-risk comorbidity and people 70 years and over [TSID11892]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over [TSID11891]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation

Previous page
1
…
145
146
Current page 147
148
149
…
594
Page 147 of 594
Next page

Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS) Clinical Knowledge Summaries
British National Formulary (BNF) British National Formulary
BNF for Children (BNFC) British National Formulary for Children
Life sciences
Library and knowledge services

What NICE does
Implementing NICE guidance
Get involved
About us
Careers
News, blogs and podcasts
Newsletters and alerts
Contact us
Leave feedback
Reusing our content
NICE UK Open Content Licence
Syndicate our content
Events

Facebook
X
YouTube
LinkedIn

Accessibility
Freedom of information
Glossary
Terms and conditions
Privacy notice
Cookies

© NICE 2026. All rights reserved. Subject to Notice of rights.